Walleye Capital LLC Cuts Holdings in Disc Medicine, Inc. (NASDAQ:IRON)

Walleye Capital LLC lowered its position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 87.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,004 shares of the company's stock after selling 182,232 shares during the quarter. Walleye Capital LLC owned about 0.09% of Disc Medicine worth $1,712,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. FMR LLC raised its position in shares of Disc Medicine by 358.7% during the 4th quarter. FMR LLC now owns 1,866,248 shares of the company's stock valued at $118,320,000 after buying an additional 1,459,434 shares during the period. State Street Corp lifted its stake in shares of Disc Medicine by 39.7% in the 3rd quarter. State Street Corp now owns 827,910 shares of the company's stock valued at $40,683,000 after purchasing an additional 235,115 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Disc Medicine during the 4th quarter worth about $5,579,000. Renaissance Technologies LLC purchased a new stake in Disc Medicine in the 4th quarter valued at about $5,479,000. Finally, Geode Capital Management LLC lifted its position in Disc Medicine by 17.6% in the third quarter. Geode Capital Management LLC now owns 474,719 shares of the company's stock valued at $23,333,000 after buying an additional 70,983 shares during the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.

Disc Medicine Price Performance

Shares of IRON traded down $0.88 during mid-day trading on Friday, reaching $45.29. The company's stock had a trading volume of 72,992 shares, compared to its average volume of 344,604. The company's 50 day moving average is $48.73 and its 200 day moving average is $55.04. The stock has a market cap of $1.57 billion, a PE ratio of -11.40 and a beta of 0.77. Disc Medicine, Inc. has a 12-month low of $25.64 and a 12-month high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.08. As a group, sell-side analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Insiders Place Their Bets

In other Disc Medicine news, Director Mona Ashiya sold 5,738 shares of Disc Medicine stock in a transaction on Monday, March 24th. The shares were sold at an average price of $54.11, for a total value of $310,483.18. Following the transaction, the director now directly owns 186,541 shares in the company, valued at approximately $10,093,733.51. The trade was a 2.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Pamela Stephenson sold 3,137 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $171,217.46. Following the sale, the insider now owns 69,529 shares of the company's stock, valued at $3,794,892.82. This trade represents a 4.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 361,690 shares of company stock valued at $19,648,094 over the last quarter. Company insiders own 4.24% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on IRON shares. TD Cowen initiated coverage on shares of Disc Medicine in a research report on Thursday, February 27th. They set a "buy" rating for the company. Cantor Fitzgerald increased their price target on shares of Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 18th. Scotiabank lifted their price objective on shares of Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a report on Monday, March 3rd. Wedbush reiterated an "outperform" rating and set a $90.00 target price (up from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $118.00 price objective on shares of Disc Medicine in a research report on Tuesday, January 21st. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Disc Medicine currently has an average rating of "Buy" and an average target price of $93.80.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.